Biliverdin modulates the expression of C5aR in response to endotoxin in part via mTOR signaling

Biochemical and Biophysical Research Communications

Volumn 449, Issue 1, 2014, Pages 94-99

  Bisht, Kavita ^a,b   Wegiel, Barbara ^b   Tampe, Jens ^a   Neubauer, Oliver ^c   Wagner, Karl Heinz ^c   Otterbein, Leo E ^b   Bulmer, Andrew C ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Inflammation; Macrophage; mTOR

Indexed keywords

BILIVERDIN; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 5A; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

MAMMALIA;

INFLAMMATION; MACROPHAGE; MTOR;

ANIMALS; ANTIOXIDANTS; BILIVERDINE; CELL LINE; ENDOTOXINS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; RECEPTOR, ANAPHYLATOXIN C5A; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84901759445     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.150     Document Type: Article

References (33)

1. B. Wegiel, C.J. Baty, D. Gallo, E. Csizmadia, J.R. Scott, A. Akhavan, B.Y. Chin, E. Kaczmarek, J. Alam, F.H. Bach, B.S. Zuckerbraun, and L.E. Otterbein Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt J. Biol. Chem. 284 2009 21369 21378
2. A.C. Bulmer, J.S. Coombes, J.T. Blanchfield, I. Toth, R.G. Fassett, and S.M. Taylor Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration Br. J. Pharmacol. 164 2011 1857 1870
3. C. Molzer, H. Huber, A. Steyrer, G. Ziesel, A. Ertl, A. Plavotic, M. Wallner, A.C. Bulmer, and K.H. Wagner In vitro antioxidant capacity and antigenotoxic properties of protoporphyrin and structurally related tetrapyrroles Free Radic. Res. 46 2012 1369 1377
4. B. Wegiel, and L.E. Otterbein Go green: the anti-inflammatory effects of biliverdin reductase Front. Pharmacol. 3 2012 47
5. A.C. Boon, C.L. Hawkins, K. Bisht, J.S. Coombes, B. Bakrania, K.H. Wagner, and A.C. Bulmer Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome Free Radic. Biol. Med. 52 2012 2120 2127
6. J.K. Sarady-Andrews, F. Liu, D. Gallo, A. Nakao, M. Overhaus, R. Ollinger, A.M. Choi, and L.E. Otterbein Biliverdin administration protects against endotoxin-induced acute lung injury in rats Am. J. Physiol. Lung Cell. Mol. Physiol. 289 2005 L1131 L1137
7. J. Kosaka, H. Morimatsu, T. Takahashi, H. Shimizu, S. Kawanishi, E. Omori, Y. Endo, N. Tamaki, M. Morita, and K. Morita Effects of biliverdin administration on acute lung injury induced by hemorrhagic shock and resuscitation in rats PLoS One 8 2013 e63606
8. B. Wegiel, D. Gallo, E. Csizmadia, T. Roger, E. Kaczmarek, C. Harris, B.S. Zuckerbraun, and L.E. Otterbein Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase Proc. Natl. Acad. Sci. U.S.A. 108 2011 18849 18854
9. A. Vink, D.P. de Kleijn, and G. Pasterkamp Functional role for toll-like receptors in atherosclerosis and arterial remodeling Curr. Opin. Lipidol. 15 2004 515 521 (Pubitemid 39336578)
10. B. Holst, A.C. Raby, J.E. Hall, and M.O. Labeta Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a Anaesthesia 67 2012 60 64
11. X. Zhang, Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J.D. Lambris, R.A. Wetsel, T. Miwa, and W.C. Song Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo Blood 110 2007 228 236 (Pubitemid 47026839)
12. J.V. Sarma, and P.A. Ward The complement system Cell Tissue Res. 343 2011 227 235
13. C. Ehrnthaller, A. Ignatius, F. Gebhard, and M. Huber-Lang New insights of an old defense system: structure, function, and clinical relevance of the complement system Mol. Med. 17 2011 317 329
14. H.D. Manthey, A.C. Thomas, I.A. Shiels, A. Zernecke, T.M. Woodruff, B. Rolfe, and S.M. Taylor Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice FASEB J. 25 2011 2447 2455
15. C.L. Basiglio, S.M. Arriaga, F. Pelusa, A.M. Almara, J. Kapitulnik, and A.D. Mottino Complement activation and disease: protective effects of hyperbilirubinaemia Clin. Sci. (Lond.) 118 2010 99 113
16. A.R. Kinderlerer, I. Pombo Gregoire, S.S. Hamdulay, F. Ali, R. Steinberg, G. Silva, N. Ali, B. Wang, D.O. Haskard, M.P. Soares, and J.C. Mason Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin Blood 113 2009 1598 1607
17. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev. 18 2004 1926 1945 (Pubitemid 39071573)
18. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, and F. Speleman Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol. 3 2002 RESEARCH0034
19. M. Guha, and N. Mackman The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells J. Biol. Chem. 277 2002 32124 32132 (Pubitemid 34969025)
20. M.C. Perianayagam, V.S. Balakrishnan, A.J. King, B.J. Pereira, and B.L. Jaber C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway Kidney Int. 61 2002 456 463 (Pubitemid 34102585)
21. H.R. Tsai, L.M. Yang, W.J. Tsai, and W.F. Chiou Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration Eur. J. Pharmacol. 498 2004 45 52
22. S.I. Gharbi, M.J. Zvelebil, S.J. Shuttleworth, T. Hancox, N. Saghir, J.F. Timms, and M.D. Waterfield Exploring the specificity of the PI3K family inhibitor LY294002 Biochem. J. 404 2007 15 21 (Pubitemid 46788080)
23. T. Weichhart, G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K.M. Stuhlmeier, T. Kolbe, T.M. Stulnig, W.H. Horl, M. Hengstschlager, M. Muller, and M.D. Saemann The TSC-mTOR signaling pathway regulates the innate inflammatory response Immunity 29 2008 565 577
24. Z. Sun, and R. Andersson NF-kappaB activation and inhibition: a review Shock 18 2002 99 106
25. V. Seow, J. Lim, A. Iyer, J.Y. Suen, J.K. Ariffin, D.M. Hohenhaus, M.J. Sweet, and D.P. Fairlie Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a J. Immunol. 191 2013 4308 4316
26. T. Mijatovic, L. Houzet, P. Defrance, L. Droogmans, G. Huez, and V. Kruys Tumor necrosis factor-alpha mRNA remains unstable and hypoadenylated upon stimulation of macrophages by lipopolysaccharides Eur. J. Biochem. 267 2000 6004 6012
27. A.N. Shakhov, M.A. Collart, P. Vassalli, S.A. Nedospasov, and C.V. Jongeneel Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages J. Exp. Med. 171 1990 35 47 (Pubitemid 20040597)
28. A.J. Gearing, P. Beckett, M. Christodoulou, M. Churchill, J. Clements, A.H. Davidson, A.H. Drummond, W.A. Galloway, R. Gilbert, and J.L. Gordon et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases Nature 370 1994 555 557 (Pubitemid 24264920)
29. K. Yamashita, J. McDaid, R. Ollinger, T.Y. Tsui, P.O. Berberat, A. Usheva, E. Csizmadia, R.N. Smith, M.P. Soares, and F.H. Bach Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts FASEB J. 18 2004 765 767
30. N.C. Riedemann, R.F. Guo, I.J. Laudes, K. Keller, V.J. Sarma, V. Padgaonkar, F.S. Zetoune, and P.A. Ward C5a receptor and thymocyte apoptosis in sepsis FASEB J. 16 2002 887 888
31. M. Wallner, A.C. Bulmer, C. Molzer, E. Mullner, R. Marculescu, D. Doberer, M. Wolzt, O.F. Wagner, and K.H. Wagner Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome Eur. J. Clin. Invest. 43 2013 912 919
32. B. Weinberger, F.E. Archer, S. Kathiravan, D.S. Hirsch, A.M. Kleinfeld, A.M. Vetrano, and T. Hegyi Effects of bilirubin on neutrophil responses in newborn infants Neonatology 103 2013 105 111
33. M.D. Maines Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings Curr. Drug Targets 11 2010 1586 1594